The significance of TLR expression and Tregs in HBV infection has not been clearly described. In this report, flow cytometry was performed to assess TLR2/4 expression on monocytes and circulating CD4 + CD25 
Introduction
Hepatitis B virus (HBV) is a hepatotropic DNA virus that infects~350 million people worldwide, with a particularly high prevalence in Asia and Africa (Lok and McMahon, 2001) . HBV infection in adults frequently results in a self-limiting, acute hepatitis that confers protective immunity and causes no further disease. In contrast, most children fail to clear the virus, resulting in chronic infection. Most chronically infected patients remain largely asymptomatic without lifethreatening liver disease, but 1-2 million people die annually due to the consequences of chronic HBV infection, including liver cirrhosis and hepatocellular carcinoma (Hoofnagle et al., 2007; Lok and McMahon, 2001) . Patients often exhibited impairment of HBV-specific T cell activity and failed to generate sufficient cellular immunity against the virus during chronic HBV infection (Chisari and Ferrari, 1995; Webster et al., 2004) . However, the precise mechanism associated with T cell tolerance is still not completely understood due to the host range limitations of HBV and the lack of small animal models.
With regard to the role of CD4 (Kinter et al., 2004 ) and hepatitis C virus (HCV) infection (Boettler et al., 2005) . According to more recently published data, CD4 + CD25 + Tregs could contribute to a sustained state of virus-specific T cell collapse, which is characteristic of chronic HBV infection (Barboza et al., 2007; Franzese et al., 2005; Kondo et al., 2006; Peng et al., 2008; Stoop et al., 2005; Xu et al., 2006; Yang et al., 2007) . However, the mechanism for modulation of CD4 + CD25 + Tregs functions during chronic HBV infection remains obscure. Because Tregs are naturally occurring, it is anticipated that the cells would be strongly influenced by innate immunity, including the activation of Toll-like receptors (TLRs) (Liu et al., 2006a; Medzhitov, Preston-Hurlburt, and Janeway, 1997) . TLRs, which are commonly expressed on monocytes, play a crucial role in early host defense. Activation of TLRs induces the expression of some kinds of cytokines and chemokines, which control activation of adaptive immune responses (Akira and Takeda, 2004 ). An abundance of experimental data also suggested that alterations in TLRs by virus might be responsible for virus-induced immune modulation. Wu et al. found that murine nonparenchymal liver cells can be activated by TLR3 and TLR4 to produce interferon-β (IFN-β) and other mediators that can potently suppress HBV replication (Wu et al., 2007 + Tregs (Liu and Zhao, 2007) . Nevertheless, the effect of TLRs to CD4 + CD25 + Tregs is still somewhat controversial. TLR2, TLR4, and TLR8 is generally thought to downregulate the function of Treg (Pasare and Medzhitov, 2003; Peng et al., 2005; Sutmuller et al., 2006 
Results

Overexpression of TLR2 and TLR4 on monocytes from HBV-infected patients
We examined peripheral blood monocytes from 42 patients with HBeAg-positive chronic hepatitis B (CHB) 16 patients with acute hepatitis B (AHB), 22 HBeAg-positive asymptomatic HBV carriers (AsC), and 20 normal controls (NC). The clinical data obtained for the enrolled subjects are listed in Table 1 . Separate CD14-positive populations of cells were gated by flow cytometry (Fig. 1A) . The level of TLR2 and TLR4 expression was measured in these cell populations, and a typical flow histogram of CD14-positive TLR expression is shown in Fig. 1B . Summary data from the enrolled volunteers are shown in Fig. 1C .
Mean fluorescence intensity (MFI) values corresponding to TLR2 were upregulated in AHB, CHB, and AsC groups compared with NC. The MFI ± standard deviation (SD) values were NC = 96.79 ± 16.84, AHB = 130.09 ± 35.37, CHB = 212.92 ± 81.72 and AsC = 161.13 ± 43.31. The MFI value evaluated for CHB patients was significantly increased compared to those of AHB patients (P b 0.001) and AsC patients (P = 0.011). A significant difference was also observed between AHB and AsC patients (P = 0.017).
The MFI values corresponding to TLR4 were also increased in AHB, CHB and AsC groups compared with NC. The MFI ± SD values were NC = 19.73 ± 5.44, AHB = 28.07 ± 5.39, CHB = 24.74 ± 8.17 and AsC = 28.96 ± 5.29 . The results revealed no significant differences between AHB and CHB and between AHB and AsC (P N 0.05).
Influence of HBeAg and HBcAg on TLR2 and TLR4 expression
To explore whether TLR2 and TLR4 could be specifically affected by HBV antigen in vitro, PBMCs from 9 of NCs and 14 of CHBs were cultured for 20 h in RPMI 1640 supplemented 10% FBS, with or without (untreated control) 2 μg/mL of purified HBeAg or 1 μg/mL of purified HBcAg, and analyzed for co-expression of CD14 and TLR2/TLR4 by flow cytometry. Doses of 1 μg/mL, 2 μg/mL, 5 μg/mL, and 10 μg/mL were tested for each antigen and optimal response was observed with 2 μg/ mL of purified HBeAg or 1 μg/mL of purified HBcAg. NC 
CHB patients
We also analyzed peripheral blood from the volunteers described above to determine the percentage of CD25 + T cells in the total CD4 + T cell population. In CHB patients, the CD4 higher in CHB patients (mean ± SD: 6.00 ± 1.24%) compared to NC (mean ± SD: 4.70 ± 1.30%) (P = 0.0048), but not compared to AHB low/− Tregs (r = −0.501, P = 0.0007, Fig. 4A ), but there was no correlation between Tregs and serum copies of HBV DNA (r = 0.243, P = 0.121, Fig. 4B ). HBV genotypes were determined by nested-PCR using typespecific primers, as described previously (Naito, Hayashi, and Abe, 2001 ) for all enrolled HBV infected patients. Among the 80 patients, 24 (30%) were genotype B, 2 (2.5%) were genotype C and 54 (67.5%) were mixed genotype B and C. No A, D, E, or F genotypes were found. This is in agreement with the characteristic geographic distribution of HBV genotypes in China. There were no significant difference in ALT values, positive rate of HBeAg, and HBV DNA value among the different genotypes (data not shown). Among 42 of CHB patients, 13 (30.95%) were genotype B, 2 (4.76%) were genotype C, and 27 (64.29%) were mixed genotype B and C. For the different genotypes among CHB patients, neither TLR2/4 expression nor Tregs frequencies showed any significant differences (Fig. 4C ). (Fig. 5, lanes 1 and 2) . When PBMCsTregs were cocultured with Tregs which had been pretreated with Pam3Csk4 (TLR2 agonist) and LPS (TLR4 agonist), cellular proliferation was significantly decreased under both anti-CD3 and HBsAg stimulation (Fig. 5, lanes 3 and 4) . Furthermore, when PBMCs-Tregs were pretreated with Pam3Csk4 and then cocultured with autologous Tregs, neither anti-CD3 nor HBsAg stimulation showed significant effects on cellular proliferation (Fig. 5, lane 6) . Interestingly, LPS-activated PBMCs-Tregs significantly decreased cellular proliferation when cocultured with Tregs stimulated by anti-CD3 but not by HBsAg (Fig. 5, lane 5) .
Discussion
In the current study, we characterized the expression levels of TLR2 and TLR4 proteins on CD14 + monocytes during acute and chronic HBV infection and observed that monocytes from patients with HBV infection expressed significantly higher levels of TLR2 and TLR4 proteins compared with those from normal controls, which consistent with earlier data obtained for TLR2 and TLR4 expression on hepatocytes from CHB patients (Guo, Wei, and Yang, 2007; Wei et al., 2008) . Because TLR2 and TLR4 were detected as both the important components of the innate immunity in humans and microbial recognition receptors, our works and others suggested that HBV infection could modify the innate immune by upregulating the expression of TLR2 and TLR4, which may also play an important role in recognition and initiation of HBV infection. In contrast to our findings, others Riordan et al., 2006; Visvanathan et al., 2007) reported that HBV downregulates the expression of TLR2 on hepatocytes, Kupffer cells, and peripheral monocytes, whereas the level of TLR4 expression did not significantly differ in response to HBV infection. To validate our results, we investigated the postulate that the immunodysregulation of TLR2 and TLR4 associated with HBV infection is partially mediated by stimulation of HBV-encoded antigens. Purified HBcAg and HBeAg were used to stimulate isolated PBMCs from NCs and CHBs, and their effect on TLR2 and TLR4 expression was determined. We found that TLR2 expression was increased by HBeAg induction in normal individuals but no significant changes were detected in CHBs. It is known that pre-C/C mRNA is one of the first transcripts to be transcribed and translated following establishment of infection, thereby making HBeAg as an early-phase viral protein product of HBV infection in the serum (Yuh, Chang, and Ting, 1992) . Therefore, during the early phase of infection, HBeAg may function as a major target for the inflammatory immune response and induce increased expression of TLR2. Once chronic infection has been established, the continual secretion of HBeAg may serve as the tolerogen, which is necessary to maintain the tolerant state. Therefore, no TLR2 response following HBeAg stimulation was detected in CHBs. Our results indicate that HBeAg may function as both an immunogen (early stage of infection) and a tolerogen (persistent infection) depending on the context of HBV infection. Interestingly, we observed that following either HBeAg or HBcAg incubation, the proportion percentages of CD14 + and CD14 + TLR2 + cells in PBMCs were decreased in both NCs and CHBs. This may be due, in partly, to the toxicity of the purified antigens. In our preliminary experiments, difference doses of antigens were tested, and an optimal response was observed with 2 μg/mL of HBeAg and 1 μg/mL of HBcAg, as a high dose of stimulus (10 μg/mL) resulted in great cell death. Our results also reveal that TLR4 showed contradictory expression profiles in response to HBcAg and HBeAg during chronic HBV infection. This result has the remarkable implication that an immunogenic difference between HBcAg and HBeAg exists. In addition, we also determined the HBV genotypes of the enrolled patients and found that the majority of them were genotype B and C, differing from Oceania, which exhibits predominantly genotype A. We presumed that the differences between our findings and those of others may be due to variations in geographic location, viral subtypes and host genetic background. Our study did not reveal a significant difference in total CD4 + CD25 + T cells in the peripheral blood of HBV-infected patients.
Recently, it has been suggested that there is an inverse relationship between the expression of Foxp3 and CD127, and in combination with surface expression of CD25 it can distinguish between human regulatory and conventional CD4 + T cells in human blood (Hartigan-O'Connor et al., 2007; Liu et al., 2006b (Barboza et al., 2007; Franzese et al., 2005; Kondo et al., 2006; Peng et al., 2008; Stoop et al., 2005; Xu et al., 2006; (Franzese et al., 2005; Stoop et al., 2005) . It may indicate that the early stage infection (first few days/weeks after infection) really determining the total number of Tregs and possible disease outcome. It is also possible that Tregs accumulate and expand locally at the site of infection, where they exert their suppressive activity (Cao et al., 2003; Yamazaki et al., 2003) . Another possibility is that a population of HBV-specific regulatory cells that differ from CD4 + CD25 + CD127 low/− Tregs might be induced during chronic HBV infection, as in Barboza's HBcAg contribute to maintain active viral replication and subvert host immune response (Barboza et al., 2007) . In addition, virus may potentially effects expression of these genes, since virus-specific Tregs displayed a distinct phenotype and CD127 and CD25 expression defines CD4 + T cell subsets are differentially in HCV and HIV infection (Dunham et al., 2008; Heeg et al., 2009 (Yu et al., 2008) .
Further studies will determine whether monitoring the three subsets of CD4 + T cells defined based on the expression of CD25 and CD127
should be used in the clinical management of HBV-infected individuals and the levels of IL-10 expression should be determined in these cells. Recent study in autoimmune liver diseases (AILD) has focused on the role of monocytes and their relationship with Tregs. Longhi et al. (2009) found that monocytes were higher in number and expressed higher levels of TLR4. Addition of Tregs in AILD enhanced monocyte migration, magnified TNF-alpha over IL-10 production and markedly increased TLR4 expression levels. Monocyte overactivation and inability of Tregs to restrain it may contribute to the loss of immune tolerance and perpetuation of the autoimmune attack in AILD. We observed that exposure of CD4 provide potential applications in the treatment of CHB. Current data is only shown at a 1:1 ratio, which would not occur in nature, however, TLR2 and TLR4 has been proved to augment the functions of Tregs in this study. Also, the specificity of TLRs agonists has not been fully established and they may have far reaching effects on the cells outside of their TLR expression profiles. In addition, the in vitro study may not have an in vivo equivalence. Thus, the mechanism of this interaction requires further investigated in vivo and molecular mechanisms for the regulation of CD4 + CD25 + Tregs via TLRs also needs to clarify.
In summary, our findings demonstrate that patients with HBV infection exhibited significant up-regulation of TLR2 and TLR4 on circulating monocytes. Exposure to HBeAg and HBcAg is able to change the expression profiles of TLR2 and TLR4. Furthermore, a marked increase in CD4 + CD25 + CD127 low/− Tregs was observed in the peripheral blood of CHB patients. Both Pam3Csk4 (TLR2 agonist)-and LPS (TLR4 agonist)-activated CD4 + CD25 + Tregs showed enhanced suppression function in CHBs. This study indicates a potentially important interaction between innate immune responses and immunoregulation during HBV infection. Further studies examining the mechanisms response for this interaction in the context of HBV infection will be critical and fruitful in guiding the development of new immunotherapeutics to treat CHB.
Materials and methods
Subjects
Blood samples were collected from 80 HBV-infected patients, including 16 patients with AHB, 42 patients with CHB, 22 of AsC. The standards for diagnoses were made according to the diagnostic standard of Chinese National Program for Prevention and Treatment of Viral Hepatitis. All patients were hospitalized or followed-up in Tangdu Hospital from May 2007 to June 2008. As a normal control, fresh blood samples were obtained from 20 healthy age and sex matched individuals. Patients who were co-infected with HIV, other hepatitis viruses, and any bacterial infection or concurrently of afflicted by immunocompromised diseases and autoimmune diseases were excluded. No patients received anti-HBV agents or immunomodulatory treatments for 6 months before sampling. The study protocol was approved by the ethics committee of Fourth Military Medical University, and written informed consent was obtained from each subject.
Virological assessment
HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HBc were determined by commercial enzyme immunoassay kits (Kehua Biotech, Shanghai, China). Serum HBV DNA was quantitated using a commercial realtime polymerase chain reaction (PCR) kit (PG Biotech, Shenzhen, China), with detection limit threshold of 500 copies/mL. HBV genotyping was performed as described previously (Naito, Hayashi, and Abe, 2001 ). was determined by flow cytometry. Cells were incubated in RPMI 1640 (Hyclone, Logan, Utah) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen GIBCO, Grand Island, NY). PBMCs were cultured (10 6 /well) in 24-well plates with or without HBeAg (ViroStat, Portland, ME; 2 μg/mL) or HBcAg (AbD Serotec, Oxford, UK; 1 μg/mL) in different wells at 37°C in a 5% CO 2 environment.
Flow cytometric analysis
PBMCs were harvested by centrifugation at 300 × g for 10 min at 4°C. To stain TLR2 and TLR4, CD14-FITC (eBioscience, San Diego, CA), TLR2-PE (eBioscience) and TLR4-APC (eBioscience) monoclonal antibodies (mAbs) were utilized. To determine the frequencies of Tregs, mAbs CD4-PerCP (BD Bioscience, San Jose, CA), CD25-FITC (BD Bioscience) and CD127-PE (eBioscience) were used. Cells were incubated and stained at 4°C in the dark for 30 min. Samples were analyzed with a four-color FACSCalibur analyzer (BD Biosciences Immunocytometry Systems). Acquisitions were performed with CellQuest Pro software (BD Biosciences Immunocytometry Systems) and analyses were performed with FlowJo version 5.7.2 for Windows (Tree Star Inc., Ashland, OR). Isotype control antibodies were used to separate positive and negative cells in the PerCP, FITC, PE, and APC fluorescence channels. (5 × 10 4 cells, respectively), and stimulated with 1 μg/mL anti-CD3
(eBioscience) or 10 μg/mL HBsAg (AbD Serotec) in 96-well plates. Before mixture, Pam3Csk4 (InvivoGen, San Diego, CA) (400 ng/mL) or LPS (InvivoGen) (100 ng/mL) were added to the culture medium of CD4 + CD25 + Tregs and PBMCs-Tregs, and the culture was maintained for 24 h and then washed twice with PBS. For proliferation test, the plate was cultured for 5 days, with replenishment of fresh medium containing 20 U/mL recombinant human (rh) IL-2 (Sigma) at day 3. Cellular proliferation was measured by Cell Counting Kit-8 (CCK-8, Alexis Biochemicals, San Diego, CA). Briefly, for the last 4 h culture, 20 μL (10% of the total volume) of CCK-8 solution were added to each well. Wells that contained known number of viable PBMCs were also prepared for creating a calibration curve. The absorbance of the samples was measured at 450 nm using Model 680 Microplate Reader (Bio-Rad, Hercules, CA).
Statistic analyses
Data were analyzed using SPSS version 13.0 for Windows. The Kruskal-Wallis H test and Dunn's multiple comparison test were used for comparison between groups. The Wilcoxon matched pairs test was used to compare TLRs expression before and after antigen stimulation. Spearman correlation analysis was performed for correlation analysis. A value of P b 0.05 was considered to indicate a significant difference. (depletion of Treg), PBMC-Treg + Treg (depletion of Treg and add back Treg at a ratio of 1:1) were used as effector cells, respectively. The effector cells were inoculated in 96-well plate at 100,000 cells per well, and stimulated by 10 μg/mL HBsAg or 1 μg/mL anti-CD3 Ab. The effects of Pam3Csk4 (TLR2 agonist) and LPS (TLR4 agonist) on both Tregs and PBMCs-Tregs were measured on cellular proliferation. Cells were cultured for 5 days. For the last 4 h, the cultures were pulsed with 10% of CCK-8. All data are shown as the mean ± standard deviation for 10 subjects in each group. The significance of differences was calculated using Dunn's multiple comparison test.
